SWTX - SpringWorks Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Stamford,
United States
Type: Equity
SWTX price evolution
SWTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $80.52 | $118.65 | $176.67 | |
| Short term investments | $303.99 | $318.55 | $303.15 | |
| Net receivables | $32.97 | $24.5 | $15.53 | $5.93 |
| Inventory | $9.83 | $7.72 | $5.22 | $3.1 |
| Total current assets | $435.11 | $431.32 | $471.8 | $500.91 |
| Long term investments | $145.44 | $145.57 | $185.34 | |
| Property, plant & equipment | $25.36 | $24.57 | $24.08 | $24.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $186.01 | $185.03 | $224.88 | |
| Total investments | $449.42 | $464.12 | $488.49 | |
| Total assets | $608.88 | $617.33 | $656.83 | $725.79 |
| Current liabilities | ||||
| Accounts payable | $9.65 | $7.89 | $7.01 | $7.4 |
| Deferred revenue | $19.55 | $19.55 | ||
| Short long term debt | $0.96 | $0.98 | $1.06 | |
| Total current liabilities | $70.61 | $54.5 | $68.92 | $78.17 |
| Long term debt | $6.1 | $5.58 | $6 | |
| Total noncurrent liabilities | $6.1 | $20.48 | $21.4 | |
| Total debt | $7.06 | $6.56 | $7.06 | |
| Total liabilities | $76.3 | $60.6 | $89.39 | $99.57 |
| Shareholders' equity | ||||
| Retained earnings | -$1075.87 | -$1022.34 | -$982.42 | -$895.03 |
| Other shareholder equity | $1.61 | -$0.52 | -$0.11 | $1.19 |
| Total shareholder equity | $556.73 | $567.44 | $626.22 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $176.67 | $68.07 | $104.53 | $147.65 |
| Short term investments | $303.15 | $524.72 | $269.54 | $361.39 |
| Net receivables | $5.93 | |||
| Inventory | $3.1 | |||
| Total current assets | $500.91 | $599.76 | $382.91 | $513.4 |
| Long term investments | $185.34 | $8.99 | $62.11 | $57.21 |
| Property, plant & equipment | $24.09 | $18.27 | $4.2 | $3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $224.88 | $30.48 | $69.58 | $62.79 |
| Total investments | $488.49 | $533.71 | $331.65 | $418.6 |
| Total assets | $725.79 | $630.24 | $452.49 | $576.2 |
| Current liabilities | ||||
| Accounts payable | $7.4 | $8.01 | $3.43 | $1.4 |
| Deferred revenue | $19.55 | $19.55 | ||
| Short long term debt | $1.06 | $0.48 | $1.16 | $1.38 |
| Total current liabilities | $78.17 | $51.05 | $29.97 | $17.6 |
| Long term debt | $6 | $4.77 | $0.13 | $1.4 |
| Total noncurrent liabilities | $21.4 | $21 | $0.13 | $1.52 |
| Total debt | $7.06 | $5.25 | $1.29 | $2.73 |
| Total liabilities | $99.57 | $72.05 | $30.1 | $19.1 |
| Shareholders' equity | ||||
| Retained earnings | -$895.03 | -$569.93 | -$292.51 | -$118.6 |
| Other shareholder equity | $1.19 | -$0.77 | -$0.31 | $0.04 |
| Total shareholder equity | $626.22 | $558.19 | $422.4 | $557.06 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $49.3 | $59.73 | $21.01 | $5.45 |
| Cost of revenue | $2.45 | $1.2 | $0.42 | |
| Gross Profit | $45.96 | $57.28 | $19.8 | $5.03 |
| Operating activities | ||||
| Research & development | $44.36 | $53.62 | $43.65 | |
| Selling, general & administrative | $57.84 | $60.11 | $59.84 | |
| Total operating expenses | $103.9 | $102.2 | $113.73 | $103.49 |
| Operating income | -$44.92 | -$93.93 | -$98.46 | |
| Income from continuing operations | ||||
| EBIT | -$39.92 | -$87.39 | -$94.32 | |
| Income tax expense | ||||
| Interest expense | $4.41 | |||
| Net income | ||||
| Net income | -$53.53 | -$39.92 | -$87.39 | -$94.32 |
| Income (for common shares) | -$39.92 | -$87.39 | -$94.32 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.45 | $35 | ||
| Cost of revenue | $0.42 | |||
| Gross Profit | $5.03 | $35 | ||
| Operating activities | ||||
| Research & development | $150.49 | $146.12 | $101.68 | $51.86 |
| Selling, general & administrative | $197.55 | $134.55 | $71.79 | $29.46 |
| Total operating expenses | $348.04 | $280.67 | $173.47 | $81.32 |
| Operating income | -$343.01 | -$280.67 | -$173.47 | -$46.32 |
| Income from continuing operations | ||||
| EBIT | -$325.1 | -$277.42 | -$173.91 | -$45.57 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$325.1 | -$277.42 | -$173.91 | -$45.57 |
| Income (for common shares) | -$325.1 | -$277.42 | -$173.91 | -$45.57 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$39.92 | -$87.39 | -$94.32 | |
| Operating activities | ||||
| Depreciation | $1.29 | $1.13 | $1.01 | |
| Business acquisitions & disposals | -$8.23 | |||
| Stock-based compensation | $26.25 | $30.46 | $25.07 | |
| Total cash flows from operations | -$41.79 | -$78.93 | -$62.7 | |
| Investing activities | ||||
| Capital expenditures | -$0.97 | -$0.58 | $2.3 | |
| Investments | $12.51 | $30.27 | -$161.51 | |
| Total cash flows from investing | $50.4 | $0.29 | $21.46 | -$159.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.37 | -$0.55 | $299.07 | |
| Net borrowings | ||||
| Total cash flows from financing | $4.11 | $3.37 | -$0.55 | $299.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$91.59 | -$38.13 | -$58.02 | $77.16 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$325.1 | -$277.42 | -$173.91 | -$45.57 |
| Operating activities | ||||
| Depreciation | $3.32 | $1.9 | $1.48 | $1.4 |
| Business acquisitions & disposals | -$2.8 | -$4.2 | -$3.5 | |
| Stock-based compensation | $94.53 | $72.97 | $38.44 | $10.03 |
| Total cash flows from operations | -$222.79 | -$161.56 | -$127.88 | -$32.19 |
| Investing activities | ||||
| Capital expenditures | -$7.38 | -$10.2 | -$2.02 | -$0.64 |
| Investments | $44.94 | -$201.2 | $85.61 | -$414.69 |
| Total cash flows from investing | $34.75 | -$215.6 | $83.59 | -$418.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $296.64 | $340.7 | $1.16 | $270.49 |
| Net borrowings | ||||
| Total cash flows from financing | $296.64 | $340.7 | $1.16 | $270.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $108.6 | -$36.46 | -$43.13 | -$180.54 |
News
Fundamentals
| Market cap | $2.79B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 74.47M |
| Revenue | $135.49M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$275.16M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | -10.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 20.61 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.69 |
|---|---|
| ROA | -42.19% |
| ROE | N/A |
| Debt/Equity | 0.16 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.16 |
| Quick ratio | 6.02 |